See the DrugPatentWatch profile for keytruda

The High Cost of Keytruda: A Barrier to Patient Access

Introduction

Immunotherapy has revolutionized the treatment of various cancers, and Keytruda (pembrolizumab) is one of the most widely used checkpoint inhibitors. Developed by Merck & Co., Keytruda has been approved for the treatment of several types of cancer, including non-small cell lung cancer, melanoma, and head and neck cancer. However, the high cost of Keytruda has raised concerns about patient access to this life-saving therapy.

The Cost of Keytruda

The cost of Keytruda varies depending on the country, region, and type of cancer being treated. In the United States, the wholesale acquisition cost (WAC) of Keytruda is around $12,500 per month, or $150,000 per year. This cost is significantly higher than other cancer treatments, making it a barrier to patient access.

Impact on Patient Access

The high cost of Keytruda has several implications for patient access:

* Limited access to treatment: Many patients may not be able to afford Keytruda, even with insurance coverage. This can lead to delayed or foregone treatment, which can worsen cancer outcomes.
* Increased financial burden: Patients and their families may face significant financial burdens, including out-of-pocket costs, copays, and deductibles.
* Racial and socioeconomic disparities: Patients from low-income backgrounds or racial and ethnic minorities may be disproportionately affected by the high cost of Keytruda, exacerbating existing health disparities.

Insights from Industry Experts

According to a report by DrugPatentWatch.com, the cost of Keytruda is a major concern for patients and healthcare providers. "The high cost of Keytruda is a significant barrier to patient access, particularly for patients with limited financial resources," said Dr. [Name], a leading oncologist.

Alternative Payment Models

To address the issue of high costs, alternative payment models have been proposed, including:

* Value-based payment: This model ties payment to the value of care provided, rather than the volume of services.
* Capitation: This model involves paying a fixed amount per patient for a set period, regardless of the services provided.
* Bundled payment: This model involves paying a single payment for a set of services, rather than separate payments for each service.

Examples of Successful Alternative Payment Models

Several healthcare systems have implemented alternative payment models with success:

* The Medicare Access and CHIP Reauthorization Act (MACRA): This law introduced a value-based payment model for Medicare, which has led to improved quality of care and reduced costs.
* The Accountable Care Organization (ACO) model: This model involves paying healthcare providers a fixed amount per patient for a set period, regardless of the services provided.

Key Takeaways

* The high cost of Keytruda is a significant barrier to patient access, particularly for patients with limited financial resources.
* Alternative payment models, such as value-based payment, capitation, and bundled payment, can help address the issue of high costs.
* Successful examples of alternative payment models include MACRA and the ACO model.

Frequently Asked Questions

1. What is the cost of Keytruda in the United States?
The wholesale acquisition cost (WAC) of Keytruda in the United States is around $12,500 per month, or $150,000 per year.
2. How does the high cost of Keytruda impact patient access?
The high cost of Keytruda can lead to delayed or foregone treatment, increased financial burdens, and racial and socioeconomic disparities.
3. What are alternative payment models?
Alternative payment models include value-based payment, capitation, and bundled payment.
4. What are successful examples of alternative payment models?
Successful examples of alternative payment models include MACRA and the ACO model.
5. How can patients access Keytruda despite the high cost?
Patients can access Keytruda through various means, including patient assistance programs, copay cards, and financial assistance programs.

Conclusion

The high cost of Keytruda is a significant barrier to patient access, particularly for patients with limited financial resources. Alternative payment models, such as value-based payment, capitation, and bundled payment, can help address the issue of high costs. Successful examples of alternative payment models include MACRA and the ACO model. Patients can access Keytruda through various means, including patient assistance programs, copay cards, and financial assistance programs.

Sources

1. DrugPatentWatch.com. (2022). Keytruda (pembrolizumab) patent expiration dates.
2. Merck & Co. (2022). Keytruda (pembrolizumab) prescribing information.
3. Centers for Medicare and Medicaid Services. (2022). Medicare Access and CHIP Reauthorization Act (MACRA).
4. Centers for Medicare and Medicaid Services. (2022). Accountable Care Organization (ACO) model.
5. National Cancer Institute. (2022). Immunotherapy for cancer.